StockNews.com assumed coverage on shares of Oragenics (NYSE:OGEN – Free Report) in a report released on Thursday. The firm issued a sell rating on the stock.
Oragenics Trading Up 1.9 %
Shares of OGEN stock opened at $1.07 on Thursday. The company’s 50-day moving average price is $1.48. Oragenics has a 12 month low of $1.00 and a 12 month high of $7.74.
Oragenics (NYSE:OGEN – Get Free Report) last issued its quarterly earnings data on Friday, March 29th. The company reported ($5.48) earnings per share (EPS) for the quarter.
About Oragenics
Oragenics, Inc, a development-stage company, engages in the research and development of antibiotics for infectious diseases in the United States. The company engages in the development and commercialization of NT-CoV2-1, an intranasal vaccine candidate that provides immunity from the novel severe acute respiratory syndrome coronavirus.
Featured Articles
- Five stocks we like better than Oragenics
- How to Start Investing in Real Estate
- MarketBeat Week in Review – 4/29 – 5/3
- Investing in Travel Stocks Benefits
- Apple’s Earnings Show Investors Its Strength and Its Weakness
- Procter & Gamble (NYSE:PG) Pulls Back After Shaky Guidance
- Bargain Alert: 3 Large Caps With Extremely Oversold RSIs
Receive News & Ratings for Oragenics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oragenics and related companies with MarketBeat.com's FREE daily email newsletter.
